Cholinergic therapy for autistic spectrum disorders

Review and case report

Elizabeta B. Mukaetova-Ladinska, William M Schaffer, Tatiana V. Bronnikova, Jodie Westwood, Elaine K. Perry

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The causes of autism are heterogeneous and still largely unknown. Currently available treatments especially for the behavioural problems frequently reported in children and adults with autistic spectrum disorder (ASD) are largely symptomatic. The cholinergic abnormalities are rather consistently reported in various molecular pathological studies, both in children and adults with ASD, and they may underlie the numerous cognitive and behavioural changes seen in ASD, e.g. cognitive changes, memory problems, attentional dysfunction etc. This raises the prospect of the use of cholinesterase inhibitors and other cholinomimetics (chemicals that can act by either directly stimulating the nicotinic or muscarinic receptors, or promote acetylcholine release) in ASD for treatment of both cognitive and behavioural changes, as well as activities of daily living and improving the overall global functioning in these subjects, similar to the effect these treatments have in various neurodegenerative and neurodevelopmental conditions (e.g. dementia and schizophrenia). We provide an overview of the current use of cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and cholinomimetics (e.g. nicotine) in the treatment of some of the cognitive and behavioral symptoms in ASD. In greater detail, we discuss the potential use of cholinomimetics in these subjects, and review the experience of Mr. A, a now twenty-eight year-old non-smoking male with a history of severe behavioral dysfunction who has been wearing a nicotine patch since July, 2005.

Original languageEnglish (US)
Title of host publicationCholinesterase: Production, Uses and Health Effects
PublisherNova Science Publishers, Inc.
Pages33-65
Number of pages33
ISBN (Print)9781621006732
StatePublished - Jan 2012

Fingerprint

Autistic Disorder
Cholinergic Agents
Rivastigmine
Cholinesterase Inhibitors
Galantamine
Tobacco Use Cessation Products
Nicotinic Receptors
Muscarinic Receptors
Therapeutics
Nicotine
Acetylcholine
Behavioral Symptoms
Neurobehavioral Manifestations
Activities of Daily Living
Data storage equipment
Dementia
Schizophrenia

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Mukaetova-Ladinska, E. B., Schaffer, W. M., Bronnikova, T. V., Westwood, J., & Perry, E. K. (2012). Cholinergic therapy for autistic spectrum disorders: Review and case report. In Cholinesterase: Production, Uses and Health Effects (pp. 33-65). Nova Science Publishers, Inc..

Cholinergic therapy for autistic spectrum disorders : Review and case report. / Mukaetova-Ladinska, Elizabeta B.; Schaffer, William M; Bronnikova, Tatiana V.; Westwood, Jodie; Perry, Elaine K.

Cholinesterase: Production, Uses and Health Effects. Nova Science Publishers, Inc., 2012. p. 33-65.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mukaetova-Ladinska, EB, Schaffer, WM, Bronnikova, TV, Westwood, J & Perry, EK 2012, Cholinergic therapy for autistic spectrum disorders: Review and case report. in Cholinesterase: Production, Uses and Health Effects. Nova Science Publishers, Inc., pp. 33-65.
Mukaetova-Ladinska EB, Schaffer WM, Bronnikova TV, Westwood J, Perry EK. Cholinergic therapy for autistic spectrum disorders: Review and case report. In Cholinesterase: Production, Uses and Health Effects. Nova Science Publishers, Inc. 2012. p. 33-65
Mukaetova-Ladinska, Elizabeta B. ; Schaffer, William M ; Bronnikova, Tatiana V. ; Westwood, Jodie ; Perry, Elaine K. / Cholinergic therapy for autistic spectrum disorders : Review and case report. Cholinesterase: Production, Uses and Health Effects. Nova Science Publishers, Inc., 2012. pp. 33-65
@inbook{7a4744212f7e4ba998007ed9d07f08b4,
title = "Cholinergic therapy for autistic spectrum disorders: Review and case report",
abstract = "The causes of autism are heterogeneous and still largely unknown. Currently available treatments especially for the behavioural problems frequently reported in children and adults with autistic spectrum disorder (ASD) are largely symptomatic. The cholinergic abnormalities are rather consistently reported in various molecular pathological studies, both in children and adults with ASD, and they may underlie the numerous cognitive and behavioural changes seen in ASD, e.g. cognitive changes, memory problems, attentional dysfunction etc. This raises the prospect of the use of cholinesterase inhibitors and other cholinomimetics (chemicals that can act by either directly stimulating the nicotinic or muscarinic receptors, or promote acetylcholine release) in ASD for treatment of both cognitive and behavioural changes, as well as activities of daily living and improving the overall global functioning in these subjects, similar to the effect these treatments have in various neurodegenerative and neurodevelopmental conditions (e.g. dementia and schizophrenia). We provide an overview of the current use of cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and cholinomimetics (e.g. nicotine) in the treatment of some of the cognitive and behavioral symptoms in ASD. In greater detail, we discuss the potential use of cholinomimetics in these subjects, and review the experience of Mr. A, a now twenty-eight year-old non-smoking male with a history of severe behavioral dysfunction who has been wearing a nicotine patch since July, 2005.",
author = "Mukaetova-Ladinska, {Elizabeta B.} and Schaffer, {William M} and Bronnikova, {Tatiana V.} and Jodie Westwood and Perry, {Elaine K.}",
year = "2012",
month = "1",
language = "English (US)",
isbn = "9781621006732",
pages = "33--65",
booktitle = "Cholinesterase: Production, Uses and Health Effects",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Cholinergic therapy for autistic spectrum disorders

T2 - Review and case report

AU - Mukaetova-Ladinska, Elizabeta B.

AU - Schaffer, William M

AU - Bronnikova, Tatiana V.

AU - Westwood, Jodie

AU - Perry, Elaine K.

PY - 2012/1

Y1 - 2012/1

N2 - The causes of autism are heterogeneous and still largely unknown. Currently available treatments especially for the behavioural problems frequently reported in children and adults with autistic spectrum disorder (ASD) are largely symptomatic. The cholinergic abnormalities are rather consistently reported in various molecular pathological studies, both in children and adults with ASD, and they may underlie the numerous cognitive and behavioural changes seen in ASD, e.g. cognitive changes, memory problems, attentional dysfunction etc. This raises the prospect of the use of cholinesterase inhibitors and other cholinomimetics (chemicals that can act by either directly stimulating the nicotinic or muscarinic receptors, or promote acetylcholine release) in ASD for treatment of both cognitive and behavioural changes, as well as activities of daily living and improving the overall global functioning in these subjects, similar to the effect these treatments have in various neurodegenerative and neurodevelopmental conditions (e.g. dementia and schizophrenia). We provide an overview of the current use of cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and cholinomimetics (e.g. nicotine) in the treatment of some of the cognitive and behavioral symptoms in ASD. In greater detail, we discuss the potential use of cholinomimetics in these subjects, and review the experience of Mr. A, a now twenty-eight year-old non-smoking male with a history of severe behavioral dysfunction who has been wearing a nicotine patch since July, 2005.

AB - The causes of autism are heterogeneous and still largely unknown. Currently available treatments especially for the behavioural problems frequently reported in children and adults with autistic spectrum disorder (ASD) are largely symptomatic. The cholinergic abnormalities are rather consistently reported in various molecular pathological studies, both in children and adults with ASD, and they may underlie the numerous cognitive and behavioural changes seen in ASD, e.g. cognitive changes, memory problems, attentional dysfunction etc. This raises the prospect of the use of cholinesterase inhibitors and other cholinomimetics (chemicals that can act by either directly stimulating the nicotinic or muscarinic receptors, or promote acetylcholine release) in ASD for treatment of both cognitive and behavioural changes, as well as activities of daily living and improving the overall global functioning in these subjects, similar to the effect these treatments have in various neurodegenerative and neurodevelopmental conditions (e.g. dementia and schizophrenia). We provide an overview of the current use of cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and cholinomimetics (e.g. nicotine) in the treatment of some of the cognitive and behavioral symptoms in ASD. In greater detail, we discuss the potential use of cholinomimetics in these subjects, and review the experience of Mr. A, a now twenty-eight year-old non-smoking male with a history of severe behavioral dysfunction who has been wearing a nicotine patch since July, 2005.

UR - http://www.scopus.com/inward/record.url?scp=84895349064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895349064&partnerID=8YFLogxK

M3 - Chapter

SN - 9781621006732

SP - 33

EP - 65

BT - Cholinesterase: Production, Uses and Health Effects

PB - Nova Science Publishers, Inc.

ER -